Interviews

Samer A. Srour, MD, discusses the results of the phase 1 TRAVERSE trial of ALLO-316 in patients with advanced renal cell carcinoma.

Benjamin Besse, MD, PhD, discusses the biomarker analysis of the phase 1/1b CHRYSALIS-2 study of amivantamab and lazertinib in patients with EGFR-mutated non–small cell lung cancer.

Danielle M. Brander, MD, discusses updated results from the ELEVATE-TN trial of acalabrutinib in patients with chronic lymphocytic leukemia.

Eric Singer, MD, discusses the relevant data that led to the approval of sunitinib in the adjuvant treatment setting for renal cell carcinoma.

In an interview with Targeted Oncology, Benjamin Besse, MD, PhD, discussed recently reported results from the phase 1/1b CHRYSALIS-2 of amivantamab and lazertinib in patients with EGFR-mutated non–small cell lung cancer.

Hatem Soliman, MD, discusses fam-trastuzumab deruxtecan-nxki and its importance for patients with HER2-positive breast cancer.

In an interview with Targeted Oncology, Ajay K. Nooka, MD, MPH, FACP, discussed data from a pooled analysis of studies from the MagnetisMM program evaluating erlanatamab in relapsed/refractory multiple myeloma.

Karim Fizazi, MD, discusses the toxicities seen with the combination of talazoparib plus enzalutamide.

Warren Swegal, MD, explains how lenvatinib in currently used in the differentiated thyroid cancer landscape.

In an interview with Targeted Oncology, Soyoung Park, MD, discusses the criteria used for determining transplant eligibility and choosing between the different types of transplants for patients with cancer.

Karim Fizazi, MD, discusses findings from the phase 3 TALAPRO-2 trial which support the recent FDA approval of talazoparib plus enzalutamide in homologous recombination repair gene-mutated metastatic castration resistant prostate cancer.

Yazan Samhouri, MD, discusses the latest advancements in the diffuse large B-cell lymphoma treatment landscape.

Bradley J. Monk, MD, FACS, FACOG, explains the implications of the phase 3 KEYNOTE-826 clinical trial.

Joshua K. Sabari, MD, discusses LY3537982 for patients with KRAS G12C-mutant advanced solid tumors.

Samer A. Srour, MD, discusses research on Orca-Q for patients undergoing haploidentical allogeneic hematopoietic stem cell transplantation.

Laura A. Dawson, MD, FRCPC, discusses key takeaways from the NRG/RTOG 1112 study of stereotactic body radiation therapy followed by sorafenib vs sorafenib alone in patients with hepatocellular carcinoma.

Sheng F. Cai, MD, PhD, discusses the results of the BEAT AML master trial in patients with acute myeloid leukemia.

In an interview with Targeted Oncology, Bradley J. Monk, MD, FACCOG, FACS, highlighted final results from the phase 3 KEYNOTE-826 trial of pembrolizumab plus chemotherapy vs chemotherapy plus placebo, with or without bevacizumab in persistent, recurrent, or metastatic cervical cancer.

Mark A. Socinski, MD, discusses his approach to managing toxicities related to osimertinib for patients with non–small cell lung cancer and EGFR mutations.

In an interview with Targeted Oncology, Se-Hoon Lee, MD, PhD, discussed long-term follow-up data from the CHRYSALIS trial in patients with EGFR-mutated advanced non–small cell lung cancer.

In an interview with Targeted Oncology, Jonathan C. Trent, MD, PhD, discussed primary and offshoot analysis data from the INTRIGUE study of patients with GIST.

Hope S. Rugo, MD, FASCO, discusses background and key findings from the phase 3 CAPItello-291 trial in breast cancer.

In an interview with Targeted Oncology, Alexander Helfand, MD discussed the current standard practice for testing patients with renal cell carcinoma and administering immunotherapy or targeted therapy.

Anna Jo Bodurtha Smith, MD, MPH, MSc, discusses her research on issues facing patients who need care for gynecologic cancers who have private insurance in the United States.

In an interview with Targeted Oncology, Joshua K. Sabari, MD, discussed drug shortages and how they are affecting clinicians and patients in the oncology space.

Lucia Masarova, MD, discusses available treatment options for patients with essential thrombocythemia.

Dennis J. Slamon, MD, discusses the key findings from the phase 3 NATALEE trial of ribociclib with endocrine therapy as adjuvant treatment in patients with HR+/HER2- early breast cancer.

Roby Thomas, MD, the ongoing shortage of the PSMA-targeted radionuclide therapy, Pluvicto and the impact it is having on prostate cancer care.

Liza C. Villaruz, MD, discusses the most promising biomarkers in the non–small cell lung cancer space.

In an interview with Targeted Oncology, Narissa Nonzee, PhD, discussed a study which focused on increasing colorectal screening rates among patients in ethnic minority communities.